Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The **ginseng nighttime black tablet** is a botanical-based formulation developed by **The Affiliated Hospital of Changchun University of Traditional Chinese Medicine** for the treatment of chronic insomnia disorder. It is primarily composed of extracts from *Panax ginseng*, specifically targeting the modulation of the central nervous system to improve sleep quality in middle-aged and elderly populations. In clinical trial settings (such as ChiCTR2200064211), it is often evaluated as part of a "black and white" tablet regimen, where the black tablet is administered at night to promote sleep induction and maintenance. The active constituents, ginsenosides, are believed to exert their effects by interacting with neurotransmitter systems, particularly the GABAergic pathway, which is critical for regulating the sleep-wake cycle.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginseng nighttime black tablet.